

Editorial

*Corresponding author

C.V. Rao, PhD

Professor of Cell Biology
Molecular and Human Genetics
Obstetrics and Gynecology
Director of Reproduction and
Development Program
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida 33199, USA
Tel. 305-348-0659
Fax: 305-348-1577
E-mail: cr Rao@fiu.edu

Volume 1 : Issue 1

Article Ref. #: 1000WHOJ1e002

Article History

Received: June 22nd, 2015

Accepted: June 24th, 2015

Published: June 25th, 2015

Citation

Rao CV. It is time to evaluate human chorionic gonadotropin for the treatment of preterm births. *Women Health Open J.* 2015; 1(1): e3-e4. doi: [10.17140/WHOJ-1-e002](https://doi.org/10.17140/WHOJ-1-e002)

Copyright

©2015 Rao CV. This is an open access article distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It is Time to Evaluate Human Chorionic Gonadotropin for the Treatment of Preterm Births

C.V. Rao*

Professor of Cell Biology, Molecular and Human Genetics, Obstetrics and Gynecology, Director of Reproduction and Development Program, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida 33199, USA

Births between 20th to 37th completed gestational weeks are considered preterm. More births occur during late (34-36 weeks) than in early (before 34 weeks) preterm period. Preterm births account for more infant deaths than any other cause. The prematurely born infants have breathing problems, feeding difficulties, cerebral palsy, developmental delays, vision problems and hearing impairment. These complications are generally more severe in early than in late preterm born infants. Preterm infants require medical care in neonatal intensive care units for several weeks after birth. The surviving infants are at a greater risk for early death and life-long neurological and cognitive difficulties. All this medical care costs billions of US healthcare dollars. In addition, parents go through considerable amount of guilt and emotional trauma.

The incidence of preterm births is about 9% in US and higher in third world countries. Despite the basic science and clinical research advances to better understand and control preterm births, the rates are increasing. The current therapies include β -androgenic agonists, calcium channel blockers, non-steroidal anti-inflammatory compounds, nitric oxide donors, oxytocin antagonists, etc. Among them Magnesium sulfate ($MgSO_4$) is a popular first line therapy. Most of these drugs are only used for about 24-48 hours, so that the patients can be treated with corticosteroids to promote fetal lung maturity. The infants with relatively mature lungs have better survival chances. There is a clear unmet need to improve upon the current therapies to better control and treat preterm births.

The paradigm shift on human chorionic gonadotropin (hCG) actions revealed that it can act on human myometrium.¹ It contains hCG/luteinizing hormone receptors and their activation results in an inhibition of contractions.¹⁻⁵ These findings are consistent with the notion that hCG promotes myometrial quiescence, which is a prerequisite for pregnancy initiation and continuation.⁵ The quiescence declines as pregnancy advances, which permits myometrial stimulants to dominate so that they can facilitate normal labor progression.⁵ The maintenance of myometrial quiescence by hCG suggests, that it could be used for suppression of prematurely activated myometrial contractions, that are responsible for preterm births.^{5,6} In fact, hCG has been shown to be effective in preventing preterm birth in a mouse model.⁷

There are now five clinical studies testing hCG in the treatment of preterm births.⁸⁻¹² Four of them were on women with active labor and the fifth was on women with a previous history of preterm births.⁸⁻¹² The studies on women with active labor were compared with $MgSO_4$ treatment.⁸⁻¹¹ The results showed that while hCG was equally effective, it did not have the side effects of $MgSO_4$.⁸⁻¹¹ In the prophylactic study, hCG was found to be equally effective as vaginal micronized progesterone tablets with a better compliance rate than progesterone.¹²

Despite this encouraging data, there are no large scale clinical trials with hCG, like those conducted with 17-hydroxy-progesterone caproate (17-OHP-C) and progesterone.^{13,14} The US Food and Drug Administration approved 17-OHP-C use in women with previous his-

tory of at least one preterm birth with singleton pregnancies. It is effective, but it is not known how it works. For example, 17-OHP-C does not inhibit myometrial contractions, it is only a weak binder to PR-A and PR-B and is not converted to progesterone in the body.¹⁵ Finally, it is not cheap and the potential side effects have not yet been completely resolved. In contrast, hCG is an inhibitor of myometrial contractions, antagonizes the oxytocin actions and the mechanisms of action are rather fairly well defined.^{2-4,16} It has minor side effects that do not generally require medical attention. In addition, it is cheap and can be made even cheaper by scaling up the production of recombinant hormone. In third world countries, where access to medical care is minimal to non-existent in rural areas, inexpensive therapies, that have a minimal or no maternal or fetal side effects, are easy to adopt.

A large multicenter, randomized, double-blind clinical trials on women with active labor and those with a previous history of preterm births are needed for hCG on a comparable scale to the ones done with 17-OHP-C and progesterone. These trials require the support of governmental and non-governmental organizations, which are dedicated to improving maternal, neonatal and child health, which is heavily impacted by preterm births. Should hCG be proven useful, it is possible to develop long acting analogs, synthetic mimetics, lozenges, delivery by nanoparticles, improving intravenous infusion conditions, combination therapies to increase the treatment effectiveness, etc. As any therapy, hCG treatment may not work in every single patient. Finally, hCG therapy may not be a panacea, but it is likely to become an important part of an obstetricians tool box to treat preterm births.

REFERENCES

- Rao CV. Paradigm shift on the targets of hCG actions. In: Cole L, Butler S, ed. Human Chorionic Gonadotropin. 2nd ed. Elsevier Limited, Chapter 15, 2015: 141-147.
- Eta E, Ambrus G, Rao ChV. Direct regulation of human myometrial contractions by human chorionic gonadotropin. *J Clin Endocrinol Metab.* 1994; 79: 1582-1586. doi: [10.1210/jcem.79.6.7989459](https://doi.org/10.1210/jcem.79.6.7989459)
- Slattery MM, Brennan C, O'Leary MJ, Morrison JJ. Human chorionic gonadotropin inhibition of pregnant human myometrial contractility. *Brit J Obstet Gynaecol.* 2001; 108: 704-708. doi: [10.1111/j.1471-0528.2001.00178](https://doi.org/10.1111/j.1471-0528.2001.00178)
- Topozada MK. Does hCG have a direct effect on the human myometrium? *Fertil Steril.* 1998; 70: S68.
- Rao ChV. Novel concepts in neuroendocrine regulation of reproductive tract functions. In: Bazer FW, ed. Endocrinology of Pregnancy, The Human Press Inc, Totowa, NJ, chapter 5, 1998: 125-144.
- Ticconi C, Piccione E, Belmonte A, Rao ChV. HCG – A new kid on the block in the prematurity prevention. *J Matern Fetal Neonatal Med.* 2006; 19: 687-692. doi: [10.1080/14767050600921315](https://doi.org/10.1080/14767050600921315)
- Kurtzman JT, Spinnato JA, Goldsmith LJ, et al. Human chorionic gonadotropin exhibits potent inhibition of preterm delivery in a small animal model. *Am J Obstet Gynecol.* 1999; 181: 853-857.
- Ali AFM, Fateena B, Ezzeta A, Badawya H, Ramadana A, El-tobge A. Treatment of preterm labor with human chorionic gonadotropin: a new modality. *Am J Obstet Gynecol.* 2000; 95: S61. doi: [10.1016/S0029-7844\(00\)00718-3](https://doi.org/10.1016/S0029-7844(00)00718-3)
- Than NG, Itakura A, Rao ChV, et al. Clinical applications of pregnancy-related proteins-a workshop report. *Placenta.* 2003; 24: S60-S64. doi: [10.1053/plac.2002.0947](https://doi.org/10.1053/plac.2002.0947)
- Lorzadeh N, Dehnoori A, Momennasab M. Human chorionic gonadotropin (hCG) versus magnesium sulfate to arrest preterm. *Yafteh.* 2004; 5: 41-46.
- Sakhavar N, Mirteimoori M, Teimoori B. Magnesium sulfate versus hCG (Human Chorionic Gonadotropin) in suppression of preterm labor. *Shiraz E-Med J.* 2008; 9: 134-140.
- Rani VU, Reddy AM, Singh A, Malathi P. Role of hCG in preventing preterm labour in comparison with vaginal progesterone. *The Indian Practitioner.* 2012; 65: 1-6.
- Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxy progesterone caproate. *New Engl J Med.* 2003; 348: 2379-2385. doi: [10.1056/NEJMoa035140](https://doi.org/10.1056/NEJMoa035140)
- Martinez de Tejada B, Karolinski A, Ocampo MC, et al. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomized doubled-blind placebo-controlled trial. *Brit J Obstet Gynecol.* 2015; 122: 80-91. doi: [10.1111/1471-0528.13061](https://doi.org/10.1111/1471-0528.13061)
- O'Brien JM. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: An evidence-based assessment. *Am J Perinatol.* 2012; 29: 665-672. doi: [10.1055/s-0032-1316444](https://doi.org/10.1055/s-0032-1316444)
- Ambrus G, Rao ChV. Novel regulation of pregnant human myometrial smooth muscle cell gap junctions by human chorionic gonadotropin. *Endocrinology.* 1994; 135: 2772-2779. doi: [10.1210/endo.135.6.7988470](https://doi.org/10.1210/endo.135.6.7988470)